Advice

Marketing Authorisation Withdrawn

On 1 May, 2018, the marketing authorization for simprevir (Olysio) was withdrawn. 

Medicine details

Medicine name:
simeprevir (Olysio)
SMC ID:
988/14
Indication:
In combination with other medicinal products for the treatment of chronic hepatitis C in adult patients.
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Infections
Submission type
Full submission
Status
Withdrawn
Date advice published:
13 October 2014
Additional notes

On 1 May 2018, the European Medicines Agency (EMA) published a statement regarding simprevir (Olysio).  The manufacturer, Janssen have withdrawn the marketing authorisation.